Valneva SE (VALN) EBITDA Margin (2021 - 2026)
Valneva SE (VALN) posted quarterly EBITDA Margin of 58.89% for Q1 2026, down 5767.0% year-on-year from 1.04% in Q1 2025, and down 4.49% on a QoQ basis from 56.36% in Q4 2025.
Valneva SE (VALN) EBITDA Margin (2021 - 2026) Analysis & Trends
Valneva SE (VALN) has reported EBITDA Margin for 6 consecutive years, with 58.89% the latest figure, recorded in Q1 2026.
- Quarterly EBITDA Margin fell 5767.0% year-over-year to 58.89% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 55.17% (down 3253.0% YoY) and the FY2025 annual result came in at 37.62%, down 5777.0% from the prior year.
- EBITDA Margin eased to 58.89% in Q1 2026 per VALN's latest filing, from 56.36% in the prior quarter.
- Over the last five years, EBITDA Margin for VALN reached as high as 34019.26% in Q4 2022 and fell as low as 24145.7% in Q3 2022.
- A 5-year average of 547.8% and a median of 44.14% in 2024 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2022 — EBITDA Margin surged 3395593 bps — and 2023, when it sank 3406509 bps.
- Year by year, EBITDA Margin stood at 34019.26% in 2022, then tumbled by 100 bps to 45.82% in 2023, then jumped by 33 bps to 30.91% in 2024, then slumped by 82 bps to 56.36% in 2025, then retreated by 4 bps to 58.89% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 58.89%, 56.36%, and 145.16% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Valneva SE | 803.90 Mn | 680.66 Mn | 5.38 Mn | -58.89% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -58.89% |
| Dec 31, 2025 | -56.36% |
| Sep 30, 2025 | -145.16% |
| Jun 30, 2025 | -11.17% |
| Mar 31, 2025 | -1.22% |
| Dec 31, 2024 | -30.91% |
| Sep 30, 2024 | -18.23% |
| Jun 30, 2024 | -44.14% |
| Mar 31, 2024 | 222.88% |
| Dec 31, 2023 | -45.82% |
| Sep 30, 2023 | -46.49% |
| Jun 30, 2023 | -39.77% |
| Mar 31, 2023 | -36.71% |
| Dec 31, 2022 | 34,019.26% |
| Sep 30, 2022 | -24,145.70% |
| Jun 30, 2022 | -164.76% |
| Mar 31, 2022 | -84.22% |
| Dec 31, 2021 | 63.33% |
| Sep 30, 2021 | -677.70% |
| Jun 30, 2021 | -213.28% |